![]() |
Name |
19,20-Epoxycytochalasin C
|
Molecular Formula | C30H37NO7 | |
IUPAC Name* |
[(1R,2S,6R,8S,10E,12R,13S,16R,17S)-17-benzyl-6,13-dihydroxy-6,8,14,15-tetramethyl-7,19-dioxo-4-oxa-18-azatetracyclo[10.7.0.01,16.03,5]nonadeca-10,14-dien-2-yl] acetate
|
|
SMILES |
C[C@H]1C/C=C/[C@H]2[C@@H](C(=C([C@@H]3[C@@]2([C@@H](C4C(O4)[C@@](C1=O)(C)O)OC(=O)C)C(=O)N[C@H]3CC5=CC=CC=C5)C)C)O
|
|
InChI |
InChI=1S/C30H37NO7/c1-15-10-9-13-20-23(33)17(3)16(2)22-21(14-19-11-7-6-8-12-19)31-28(35)30(20,22)27(37-18(4)32)24-26(38-24)29(5,36)25(15)34/h6-9,11-13,15,20-24,26-27,33,36H,10,14H2,1-5H3,(H,31,35)/b13-9+/t15-,20-,21-,22-,23+,24?,26?,27+,29-,30-/m0/s1
|
|
InChIKey |
ZOSGFLUFAVFHCM-WSRKEQNVSA-N
|
|
Synonyms |
19,20-Epoxycytochalasin C; [(1R,2S,6R,8S,10E,12R,13S,16R,17S)-17-benzyl-6,13-dihydroxy-6,8,14,15-tetramethyl-7,19-dioxo-4-oxa-18-azatetracyclo[10.7.0.01,16.03,5]nonadeca-10,14-dien-2-yl] acetate; 189351-79-9; J-012218
|
|
CAS | NA | |
PubChem CID | 126456219 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 523.6 | ALogp: | 1.3 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 126.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 38 | QED Weighted: | 0.316 |
Caco-2 Permeability: | -5.233 | MDCK Permeability: | 0.00004130 |
Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.997 |
Human Intestinal Absorption (HIA): | 0.571 | 20% Bioavailability (F20%): | 0.071 |
30% Bioavailability (F30%): | 0.615 |
Blood-Brain-Barrier Penetration (BBB): | 0.104 | Plasma Protein Binding (PPB): | 95.82% |
Volume Distribution (VD): | 1.252 | Fu: | 6.57% |
CYP1A2-inhibitor: | 0.013 | CYP1A2-substrate: | 0.079 |
CYP2C19-inhibitor: | 0.062 | CYP2C19-substrate: | 0.556 |
CYP2C9-inhibitor: | 0.051 | CYP2C9-substrate: | 0.047 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.164 |
CYP3A4-inhibitor: | 0.772 | CYP3A4-substrate: | 0.387 |
Clearance (CL): | 5.443 | Half-life (T1/2): | 0.326 |
hERG Blockers: | 0.071 | Human Hepatotoxicity (H-HT): | 0.9 |
Drug-inuced Liver Injury (DILI): | 0.926 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.514 | Maximum Recommended Daily Dose: | 0.806 |
Skin Sensitization: | 0.073 | Carcinogencity: | 0.023 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.238 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005174 | ![]() |
1.000 | D0V3ZA | ![]() |
0.268 | ||
ENC003619 | ![]() |
1.000 | D0SP3D | ![]() |
0.267 | ||
ENC005175 | ![]() |
0.778 | D01TSI | ![]() |
0.261 | ||
ENC003763 | ![]() |
0.778 | D09NNH | ![]() |
0.261 | ||
ENC005506 | ![]() |
0.778 | D0O5WP | ![]() |
0.261 | ||
ENC004463 | ![]() |
0.752 | D0W7RJ | ![]() |
0.255 | ||
ENC005505 | ![]() |
0.748 | D0D4YZ | ![]() |
0.255 | ||
ENC004310 | ![]() |
0.736 | D06CWH | ![]() |
0.253 | ||
ENC001886 | ![]() |
0.713 | D0C4RB | ![]() |
0.250 | ||
ENC002763 | ![]() |
0.664 | D02HSB | ![]() |
0.248 |